141 related articles for article (PubMed ID: 20143007)
1. Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab).
Bruzzese V; Pepe J
Reumatismo; 2009; 61(4):306-8. PubMed ID: 20143007
[TBL] [Abstract][Full Text] [Related]
2. [Rituximab treatment of rheumatoid arthritis: new evidence].
Nasonov EL
Ter Arkh; 2009; 81(6):82-91. PubMed ID: 19663200
[TBL] [Abstract][Full Text] [Related]
3. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20).
Devauchelle-Pensec V; Pennec Y; Morvan J; Pers JO; Daridon C; Jousse-Joulin S; Roudaut A; Jamin C; Renaudineau Y; Roué IQ; Cochener B; Youinou P; Saraux A
Arthritis Rheum; 2007 Mar; 57(2):310-7. PubMed ID: 17330280
[TBL] [Abstract][Full Text] [Related]
4. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease.
El Fassi D; Nielsen CH; Kjeldsen J; Clemmensen O; Hegedüs L
Gut; 2008 May; 57(5):714-5. PubMed ID: 18408106
[No Abstract] [Full Text] [Related]
5. Therapeutic effectiveness of minimal doses of rituximab in a patient with rheumatoid arthritis.
Bruzzese V
Int J Immunopathol Pharmacol; 2011; 24(1):265-7. PubMed ID: 21496414
[TBL] [Abstract][Full Text] [Related]
6. [Targeting CD20 in rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
[TBL] [Abstract][Full Text] [Related]
7. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
Shaw T; Quan J; Totoritis MC
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii55-9. PubMed ID: 14532151
[No Abstract] [Full Text] [Related]
8. CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.
Tran L; Huitema AD; van Rijswijk MH; Dinant HJ; Baars JW; Beijnen JH; Vogel WV
Hum Antibodies; 2011; 20(1-2):29-35. PubMed ID: 21558621
[TBL] [Abstract][Full Text] [Related]
9. [Anti-CD20 antibody therapy for inflammatory immune diseases].
Tanaka Y
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1801-6. PubMed ID: 17037318
[No Abstract] [Full Text] [Related]
10. Rituximab: therapeutic benefit! Vitamin R?
Mo C; Vire B; Wiestner A
Semin Hematol; 2010 Apr; 47(2):105-6. PubMed ID: 20350656
[No Abstract] [Full Text] [Related]
11. Rituximab for rheumatoid arthritis.
Okamoto H; Kamatani N
N Engl J Med; 2004 Oct; 351(18):1909; author reply 1909. PubMed ID: 15509828
[No Abstract] [Full Text] [Related]
12. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.
Popa C; Leandro MJ; Cambridge G; Edwards JC
Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244
[TBL] [Abstract][Full Text] [Related]
13. [Rituximab (MabThera) as treatment of active rheumatoid arthritis].
El Fassi D; Nielsen CH; Bendtzen K
Ugeskr Laeger; 2006 Nov; 168(47):4079-81. PubMed ID: 17134602
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
[TBL] [Abstract][Full Text] [Related]
15. B-cell: a logical target for treatment of rheumatoid arthritis.
Youinou P; Jamin C; Saraux A
Clin Exp Rheumatol; 2007; 25(2):318-28. PubMed ID: 17543163
[TBL] [Abstract][Full Text] [Related]
16. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis.
Dörner T; Isenberg D; Jayne D; Wiendl H; Zillikens D; Burmester G;
Autoimmun Rev; 2009 Dec; 9(2):82-9. PubMed ID: 19716441
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1.
Hassan R; Williams-Gould J; Watson T; Pai-Scherf L; Pastan I
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):16-8. PubMed ID: 14734446
[TBL] [Abstract][Full Text] [Related]
18. Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab.
Markatseli TE; Kaltsonoudis ES; Voulgari PV; Zioga A; Drosos AA
Clin Exp Rheumatol; 2009; 27(6):996-8. PubMed ID: 20149320
[TBL] [Abstract][Full Text] [Related]
19. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis.
Foran JM; Norton AJ; Micallef IN; Taussig DC; Amess JA; Rohatiner AZ; Lister TA
Br J Haematol; 2001 Sep; 114(4):881-3. PubMed ID: 11564080
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
